China-Based Heparin Prompts Outsourcing Worries
This article was originally published in PharmAsia News
The problems with Chinese-made ingredients for the heparin blood-thinner drug highlight one peril of drug makers outsourcing production elements. Heparin recalls have been announced in six countries where regulators have been moved to consider the source, China, which itself has increased drug safety efforts. China and India are among developing countries still developing their systems for safeguarding drug production. One American safe-medicine advocate said the heparin problem was "just the tip of the iceberg" where sensitive drugs are concerned. (Click here for more
You may also be interested in...
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.